Phase 2 Alectinib preliminary results

Article published February 17, 2016. Phase 2 study of Alectinib is ongoing and patients are still being treated.  Patients enrolled from September 2013 to August 2014.

All 69 patients had been pretreated with Crizotinib. Study done in USA and Canada. Objective response rate of 48%. Article summary lists most common side effects.

http://www.ncbi.nlm.nih.gov/pubmed/26708155

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Lung cancer, Potential Treatments, Research, Side Effects. Bookmark the permalink.

Leave a Reply